Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vanta BioscienceBOM:540729 50 Market Cap is ₹179.86 Mil as of Jul. 21, 2026. GuruFocus rates BOM:540729 with a GF Score™ of 50/100 and a GF Value™ of ₹11.97 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 217 Medical Diagnostics & Research companies, Vanta Bioscience ranks worse than 93.55% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Vanta Bioscience's share price for the quarter that ended in Mar. 2026 was ₹15.15. Vanta Bioscience's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 7.11 Mil. Therefore, Vanta Bioscience's market cap for the quarter that ended in Mar. 2026 was ₹107.75 Mil.
Vanta Bioscience's quarterly market cap
increased
from Mar. 2025 (₹139.62 Mil) to Sep. 2025 (₹172.54 Mil) but then
declined
from Sep. 2025 (₹172.54 Mil) to Mar. 2026 (₹107.75 Mil).
Vanta Bioscience's annual market cap
declined
from Mar. 2024 (₹403.97 Mil) to Mar. 2025 (₹139.62 Mil) and
declined
from Mar. 2025 (₹139.62 Mil) to Mar. 2026 (₹107.75 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Vanta Bioscience's Enterprise Value for Today is ₹559.29 Mil.
Vanta Bioscience (BOM:540729) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Vanta Bioscience Market Cap Related Terms
Vanta Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Vanta Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540729 vs TMO, DHR, IDXX: Market Cap Comparison
For the Diagnostics & Research subindustry, Vanta Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanta Bioscience Market Cap vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Vanta Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Vanta Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Vanta Bioscience's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanta Bioscience (BOM:540729) has a Market Cap of ₹179.86 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vanta Bioscience and its competitors. According to the industry distribution chart, Vanta Bioscience ranks #203 out of 217 companies in the Medical Diagnostics & Research industry, placing it in the top 93.5%.
Is Vanta Bioscience's Market Cap too high?
Vanta Bioscience's current Market Cap is ₹179.86 Mil. Based on the distribution chart, Vanta Bioscience ranks #203 out of 217 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Vanta Bioscience has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanta Bioscience's Market Cap compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Vanta Bioscience ranks #203 out of 217 companies for Market Cap. This places Vanta Bioscience in the lower half of its industry. The industry median Market Cap is 56.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Diagnostics & Research company?
The median Market Cap among Medical Diagnostics & Research companies is 56.47, based on 217 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Vanta Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Market Cap is 56.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanta Bioscience's current Market Cap is ₹179.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanta Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Vanta Bioscience (BOM:540729) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹11.97, compared to a current price of ₹25.29 — trading 111.3% above its estimated fair value. The current Market Cap is ₹179.86 Mil. Vanta Bioscience's overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Vanta Bioscience (BOM:540729), the current Market Cap is ₹179.86 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanta Bioscience (BOM:540729) Overvalued in 2026?
Based on GuruFocus' analysis, Vanta Bioscience stock appears to be overvalued.
The current stock price of ₹25.29 is trading 111.3% above its estimated GF Value™ of ₹11.97.
GuruFocus considers Vanta Bioscience to be Significantly Overvalued.
Key valuation signals for BOM:540729:
Market Cap: ₹179.86 Mil
GF Value™: ₹11.97 vs. price of ₹25.29 (111.3% above fair value)
No single metric tells the full story. See the BOM:540729 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanta Bioscience Ltd is a full-service preclinical contract research organization based in Chennai, India, providing preclinical safety assessment services for the pharmaceutical, medical devices, nutraceuticals, biotech, agrochemicals, cosmetics, chemical, and feed additive industries. Established as a center of excellence in GLP-compliant toxicology and safety assessment, the company supports clients through toxicology studies, batch release tests, biocompatibility evaluations, agro-chemical and chemical safety assessments, and diet formulation services. It also offers testing and contract research services in clinical and pre-clinical research, biopharma studies, analytical testing, and environmental assessments.
50GF Score
Get the complete analysis for BOM:540729
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540729 has been successfully added to your 
